Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Regeneron Pharmaceuticals, Inc.

< Previous 1 2 3 4 5 6 Next >
Regeneron Showcases Advances Across Oncology Portfolio and Pipeline at ESMO, Highlighting Novel and Patient-Focused Approach for Difficult-to-Treat Cancers
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
DB-OTO Results in the New England Journal of Medicine Showcase Dramatic and Sustained Improvements in Hearing and Speech Perception in Children with Profound Genetic Hearing Loss
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
Libtayo® (cemiplimab-rwlc) Approved in the U.S. as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
Regeneron to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on October 28, 2025
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
Evkeeza® (evinacumab-dgnb) ANGPTL3 Antibody Approved in the U.S. for Children as Young as 1 Year Old with Ultra-Rare Form of High Cholesterol
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
Dupixent® (dupilumab) to Treat Chronic Spontaneous Urticaria (CSU) Advances in EU with Positive CHMP Opinion
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN SNY
Regeneron Donates Ebola Treatment for Use in Countries Most at Risk of Outbreaks
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
Results from Phase 2 COURAGE Trial Demonstrating Potential to Improve Quality of GLP-1 receptor agonist-induced Weight Loss by Preserving Lean Mass, Presented at EASD
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
Regeneron Announces Positive Phase 3 Trial in Adults with Ultra-Rare Genetic Disorder Fibrodysplasia Ossificans Progressiva (FOP), Demonstrating that Garetosmab Prevents Greater than 99% of Abnormal Bone Formation
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
Libtayo® (cemiplimab) Plus Chemotherapy Results at Five Years Reinforce Significant and Durable Improvements in Survival Outcomes for Advanced Non-small Cell Lung Cancer
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
Regeneron Advances Allergy Pipeline with Two Positive Phase 3 Trials Evaluating First-in-Class Antibody-Blockers of Cat and Birch Allergies
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
Regeneron Announces Updated Presentation Time for Upcoming Investor Conference
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
Regeneron Announces Positive Results from Phase 3 Trial in Generalized Myasthenia Gravis
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
EYLEA HD® (aflibercept) Injection 8 mg Applications for Expanded U.S. Label and Prefilled Syringe Receive FDA Review Period Extension
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
Regeneron Announces Investor Conference Presentations
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
Regeneron Reports Second Quarter 2025 Financial and Operating Results
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
Regeneron Announces the 2025 Winners of the Regeneron Prize for Creative Innovation
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
Lynozyfic™ (linvoseltamab-gcpt) Receives FDA Accelerated Approval for Treatment of Relapsed or Refractory Multiple Myeloma
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
Regeneron to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2025
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
Regeneron Announces First-of-its-Kind Donation Matching Program with Independent Charitable Patient Assistance Organization
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
Dupixent® (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4 Head-to-Head Respiratory Trial
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN SNY
Dupixent® (dupilumab) Data at Revolutionizing Atopic Dermatitis (RAD) Conference Reinforce Use in Atopic Dermatitis Patients with Skin of Color
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
Regeneron Expands Clinical-Stage Obesity Portfolio with Strategic In-Licensing of Novel Dual GLP-1/GIP Receptor Agonist
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
Interim Results from Ongoing Phase 2 COURAGE Trial Confirm Potential to Improve the Quality of Semaglutide (GLP-1 receptor agonist)-induced Weight Loss by Preserving Lean Mass
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
Libtayo® (cemiplimab) Phase 3 Data in the Adjuvant Treatment of Post-Surgical High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) Have Potential to Be Practice-Changing
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
Itepekimab Met Primary Endpoint in One of Two Chronic Obstructive Pulmonary Disease (COPD) Phase 3 Trials
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN SNY
Linvoseltamab in Combination with Carfilzomib or Bortezomib Shows Promising Initial Results in Earlier Lines of Treatment for Relapsed/Refractory Multiple Myeloma
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
Regeneron Enters into Asset Purchase Agreement to Acquire 23andMe® for $256 Million; Plans to Maintain Consumer Genetics Business and Advance Shared Goals of Improving Human Health and Wellness
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
75th Annual Regeneron International Science and Engineering Fair Awards Teen Scientists from Around the World More Than $9 Million in 2025 Competition
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.